Assessing the value of precision medicine health technologies to detect and manage melanoma.

"Competing interests H Peter Soyer is a shareholder of MoleMap NZ and E‐Derm‐Consult and undertakes regular teledermatological reporting for both companies; is a medical consultant for Canfield Scientific, MoleMap Australia, Blaze Bioscience and Revenio Research; and is a medical advisor for First Derm."

"Rachael Morton is supported by a National Health and Medical Research Council (NHMRC) Emerging Leadership‐2 Fellowship (1194703). We acknowledge the Australian Cancer Research Foundation for financial support to the ACEMID program. Victoria Mar received the NHMRC Clinical Trials and Cohort Studies Grant (2001517), and Monika Janda received the NHMRC Centre of Research Excellence (2006551) and the NHMRC Synergy Grant (2009923). We thank the following ACEMID Team members for their contribution to this manuscript: Anne Cust (Daffodil Centre, University of Sydney and Cancer Council NSW), Joanne Aitken (Cancer Council Queensland); Richard Scolyer (Melanoma Institute Australia, University of Sydney), Pascale Guitera (Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital), Liam Caffery (Centre for Online Health, University of Queensland), Rory Wolfe (Monash University), and Graham Mann (John Curtin School of Medical Research, Australian National University)."